MOTS-cvsRetatrutide
MOTS-c vs Retatrutide — independent comparison of uses, administration, pricing across providers, and key differences. Last reviewed April 21, 2026.
Quick Verdict
Based on clinical evidence and real patient data
A mitochondria-derived peptide encoded within the mitochondrial genome. MOTS-c regulates metabolic homeostasis, enhances insulin sensitivity, and has shown promise in extending healthspan in animal studies. Levels naturally decline with age.
A next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show weight loss exceeding tirzepatide, positioning it as the most potent anti-obesity peptide in development.
Best choice depends on your insurance, budget, and treatment history.Take the quiz to get a personalized recommendation.
MOTS-c vs Retatrutide: At a Glance
Full comparison across all key factors.
| Factor | MOTS-c | RetatrutideALLY PICK |
|---|---|---|
| Category | anti-aging | weight-loss |
| Also Known As | Mitochondrial Open Reading Frame of the 12S rRNA-c | LY3437943 |
| Administration | Subcutaneous injection | Subcutaneous injection (weekly) |
| Prescription | Required | Required |
| Providers | 2 providers | 3 providers✓ Better |
| Common Uses |
|
|
Data sourced from FDA prescribing information and peer-reviewed clinical trials. Prices reflect telehealth platform costs as of April 21, 2026. See our methodology.
Pricing by Provider
2 providers offer both MOTS-c and Retatrutide.
| Provider | MOTS-c | Retatrutide | Consultation | Lab Testing |
|---|---|---|---|---|
 | $220/monthly | $450/monthly | Video Telehealth | Yes |
 | $280/monthly | $550/monthly | Video Telehealth | Yes |
 | Not offered | $480/monthly | Video Telehealth | Yes |
Key Differences
MOTS-c
A mitochondria-derived peptide encoded within the mitochondrial genome. MOTS-c regulates metabolic homeostasis, enhances insulin sensitivity, and has shown promise in extending healthspan in animal studies. Levels naturally decline with age.
Retatrutide
More ProvidersA next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show weight loss exceeding tirzepatide, positioning it as the most potent anti-obesity peptide in development.
Which Is Right for You?
Choose MOTS-cif…
- You want a anti-aging medication
- You prefer subcutaneous injection administration
- 2 providers available on our platform
- Your primary goal is metabolic health
- Your primary goal is insulin sensitivity
Choose Retatrutideif…
- You want a weight-loss medication
- You prefer subcutaneous injection (weekly) administration
- You want more provider options (3 available)
- Your primary goal is weight loss
- Your primary goal is metabolic health
Frequently Asked Questions
What is the difference between MOTS-c and Retatrutide?
Which is cheaper, MOTS-c or Retatrutide?
Can I switch from MOTS-c to Retatrutide?
Medical Disclaimer
This comparison is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication. Individual results may vary. The information presented reflects publicly available data and may not account for your specific health situation.
Related Guides
MOTS-c Peptide Guide 2026: Metabolic Health, Longevity & Telehealth Providers
Read guide →Read guide →Retatrutide: The Triple-Agonist GLP-1 That Could Change Everything
Complete guide to retatrutide — Eli Lilly's triple-agonist (GLP-1/GIP/glucagon) with 28.7% weight loss in trials. Clinical data, how it compares, and when it might be available.
Read guide →Retatrutide Cost: What Will Eli Lilly's Triple-Agonist Cost When It Launches?
No official pricing exists for retatrutide — it hasn't been FDA-approved. Based on Lilly's existing portfolio, expect a list price of $1,000-1,500/mo with LillyDirect pricing potentially reducing that to $299-449/mo. Here's what we know, what we can project, and how to prepare.
Read guide →